– CANADA, Halifax – 3D BioFibR Inc., a leading innovator in the field of tissue engineering and regenerative medicine, today announced the appointment of Dr. Michael Francis (Ph.D.) to its Board as an Independent Director, bringing a wealth of experience in research and development and partnering of novel products using advanced collagen fiber manufacturing technologies.
About Dr. Michael Francis
As co-founder of Embody Inc., Dr. Francis invented and developed Embody’s collagen-based bio-fabrication technology and served as the primary investigator on ~$23M in grants (DARPA, NIH, Army, AFWERX), helping to raise $31M in investor funding on the way to a $275M exit from Zimmer Biomet.
“3D BioFibR is advancing a completely novel way of manufacturing collagen fibers for the tissue engineering and regenerative medicine market,” said Dr. Francis. “From a scale and quality perspective, I think this novel approach has a lot to offer. I am thrilled to join the Board and work with 3D BioFibR to explore how these novel materials can make a meaningful contribution to the field of regenerative medicine.”
About 3D BioFibR
3D BioFibR produces high-value collagen fibers at commercial scales for a variety of tissue engineering and medical applications. The Company’s proprietary dry-spinning process produces fibers that are best in-class in claw strength, diameter, and quality perspective, recreating the natural appearance, structure, and function of collagen fibers. This manufacturing process is at least 3,600x faster than competing manufacturing processes, making its collagen fibers accessible for an increasing number of biomedical applications in the growing tissue engineering market.
For more information: https://3dbiofibr.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
